Periodic Safety Update Report: Requirements under EU MDR

Chandini Valiya Kizhakkeveetil
A pen and notepad, resting on a laptop.

As part of the ongoing efforts to ensure the safety and performance of medical devices, the Post-Market Surveillance (PMS) system under the European Union Medical Device Regulation (EU MDR) has become more stringent. One of the components of PMS is the periodic safety update report (PSUR), introduced in Article 86 of MDR 2017/745, which is now a cornerstone of compliance and device lifecycle management.

Interestingly, while PSURs have been mandatory for pharmaceutical products for some time, they have only recently become a requirement for medical devices under EU MDR.

What is a Periodic Safety Update Report (PSUR)?

A PSUR provides a concise analysis of PMS data to assess the benefit-risk profile, incorporating new or emerging information. By evaluating global safety data and summarising PMS findings, a PSUR ensures timely identification of risks and supports regulatory compliance.

Objectives of the PSUR

Under the EU MDR (2017/745), manufacturers are required to submit PSURs with the goal of enhancing medical devices and maximising the benefits they provide to patients.

The objectives include:

  • Identification and evaluation of changes in the benefit-risk profile
  • To provide information on Preventive or Corrective Actions (CAPA) according to Article 83(4).

Content of the PSUR

The key requirements of a PSUR are set out in Article 86(1) and Annex III. These include the following:

  • The conclusions of the benefit-risk determination
  • The main findings of the post-market clinical follow-up (PMCF)
  • The volume of sales of the device, an estimate of the size and other characteristics of the population using the device, and, where practicable, the usage frequency of the device.

Which devices need a PSUR?

According to the EU MDR, the following groups of devices require a PSUR:

  • MDR compliant devices
    • Class IIa, IIb and III devices
    • Custom-made devices falling within Class IIa, Class IIb and Class III
    • Annex XVI devices falling within Class IIa, IIb and Class III certified under MDR,
  • Legacy devices placed on the market before or after 26 May 2021 under Article 120(3).

Class I MDR devices and Class I legacy devices are excluded from this requirement.

Unsure which classification your device falls under? Check out our quick guide.

Frequency of PSUR submission

Classification Frequency Submission
Class IIa Every two years Submit to Notified Body
Class IIb non-implantable devices Annually Submit to Notified Body
Class IIb implantable devices Annually Submit via EUDAMED to Notified Body
Class III Annually Submit via EUDAMED to Notified Body

Reporting to competent authorities

Data collection for the PSUR should commence from the first certification date of the MDR device. Manufacturers of class III devices or implantable devices are required to submit their PSURs electronically through the European Database on Medical Devices (EUDAMED) to the Notified Body involved in the conformity assessment.

For Class IIa and IIb non-implantable devices, they are made available to the Notified Body involved in the conformity assessment and to competent authorities during surveillance activities or upon request.

Action points for manufacturers

  • Ensure continuous data collection processes focusing on clinical data and adverse event reporting
  • Implement a robust risk management process to assess the device’s safety and performance
  • Review and update the PMS plan to ensure that PSURs meet regulatory expectations
  • Maintain open communication with competent authorities to submit reports and address any identified risks promptly.

Ensuring compliance with EU MDR PSUR requirements not only helps mitigate regulatory risks but also enhances the safety of medical devices on the market. By proactively implementing a comprehensive PMS process, manufacturers can enhance device performance, improve patient outcomes, and meet EU MDR expectations.

Stay ahead of regulatory requirements—assess your PSUR process today. Contact us for a free and confidential discussion on how we can support you in meeting your MDR requirements.

Related articles

  1. An EU flag on a pole flies between two US flags against a blue sky.

    Webinar: From USA to Europe - Accelerating Your Path to the Medical Device Market

    We showed you how to quickly transform your U.S. regulatory work into a compliant EU MDR submission.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer
  2. A poster frame for our Clinical Evaluation video series featuring Paul Hercock.

    Guide to Clinical Evaluation: Common Pitfalls & Useful Resources

    Part 5 - In the final video from this series, we explore five major pitfalls that often derail clinical evaluations.

    Dr Paul Hercock Dr Paul Hercock Chief Executive Officer
  3. A US-style 'changes ahead' warning road sign.

    Device Modifications: When a Simple Change Becomes a Regulatory Nightmare

    As regulatory consultants we understand how minor modifications to a device can often cause disproportionate disruption.

    Kamiya Crabtree Kamiya Crabtree Regulatory Medical Writer
  4. Webinar announcement poster.

    Webinar: Regulatory & Cybersecurity Essentials for medical device software and AI-enabled devices

    Our webinar with Cyber Alchemy addressed bringing AI-enabled medical devices to market with both the right regulatory and cybersecurity foundations.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  5. A simple jigsaw with iconography representing growth printed on it.

    Leveraging Post-Market Surveillance Data for Continuous Improvement

    PMS isn’t just about compliance, it’s an opportunity for improvement, enhance patient safety & innovate.

    Shen May Khoo Shen May Khoo Regulatory Project Lead
  6. A poster frame for our Clinical Evaluation video series featuring Dr. W. Brambley.

    Guide to Clinical Evaluation: CEP Strategy & CER Structure

    Part 4 - We explore how these guide reviewers through the evidence that supports safey, performance, and conformity.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  7. A checklist being ticket-off in pen.

    The Critical Role of Pre-Submission Reviews in EU MDR Clinical Evaluations

    Ensuring your CER is robust and aligned with current standards is critical. How much Clinical Evidence is enough?

    Sandra Gopinath Sandra Gopinath Chief Regulatory Officer
  8. A poster frame for our Clinical Evaluation video series featuring Dr. W. Brambley.

    Guide to Clinical Evaluation: The State-of-the-Art (SOTA) Literature Review

    Part 3 - This is core of a sucessful submission. Will demystifies the process and explains how it supports clinical evaluation.

    Dr Will Brambley Dr Will Brambley Lead Medical Writer
  9. An orange tabletop with wooden question mark blocks laid upon it.

    Regulatory Update: EU Borderline & Classification Manual for medical devices v4

    New examples sharpen the distinction between medical devices and other product categories, such as pharmacologically active substances and aesthetic-only products.

    Chandini Valiya Kizhakkeveetil Chandini Valiya Kizhakkeveetil Regulatory Medical Writer

More articles

Need help producing compliant CEPs & CERs? We are offering FREE CEPs to 5 qualifying applicants per week

Get your free CEP